# miR-29: A brain homeostasis molecule for Alzheimer’s disease prevention

> **NIH NIH R01** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $622,753

## Abstract

Project Summary
 One of the underexplored aspects of neuronal biology is that as postmitotic neurons become mature, they
undergo dynamic changes to ensure that the mature nervous system is capable of long-term survival and
function. Understanding these mechanisms that are critical for the long-term homeostasis of the adult brain is
important as their dysfunction could increase the vulnerability of neurons to age-related neurodegeneration,
such as Alzheimer’s disease (AD).
 We have identified miR-29 as a microRNA that is strikingly induced during brain maturation. In contrast
to the high miR-29 levels that are maintained in the normal adult brains, miR-29 levels are reduced in
Alzheimer’s Disease patients. miR-29 is recognized to target many of the genes in the AD pathways including
BACE1, NAV3, and IFITM3.
 To evaluate the functional importance of miR-29, we generated mice in which miR-29 can be conditionally
deleted. Mice deficient for miR-29 in the brain are born normal but then progressively decline, exhibiting
neurological defects and early lethality. These results show that miR-29 is physiologically important for the
maintenance of long-term homeostasis in the adult brain. Reduction in miR-29 levels could therefore increase
the vulnerability of mature neurons to become dysfunctional in the context of AD.
 We have recently generated mice in which miR-29 levels can be conditionally reduced in the adult brain.
Thus, the overall focus of our proposal is to define the consequences of miR-29 reduction in the adult brain and
to evaluate the therapeutic potential of miR-29 for AD. Specifically, in Aim 1, we will conduct single-cell RNA-
seq analysis to identify the specific cell types that are most impacted by miR-29 reduction in the adult brain.
We will also examine if miR-29 reduction causes changes in dendritic spine morphology and neuronal
arborization in the adult brain. Our results have revealed that an essential function of miR-29 is to regulate
non-canonical (non-CG), CH methylation in the mature brain via its targeting of the methyltransferase
Dnmt3a, where the loss of miR-29 results in CH hypermethylation and reprogramming of gene expression. In
Aim 2, we will examine if CH hypermethylation is a common feature of AD in three distinct mouse models of
AD and AD patient brain samples. Our hypothesis is that restoring miR-29 levels would have therapeutic
benefit for AD. Thus, in Aim 3, we will examine whether AAV-mediated delivery of miR-29 confers benefit in
human stem cell and preclinical mouse models of AD.
 Overall, we are excited to be working on a molecule, miR-29, that has a unique and essential function in
the mature brain. Our studies will help define its mechanisms of action as well as evaluate its therapeutic
potential in the context of Alzheimer’s Disease.

## Key facts

- **NIH application ID:** 10817747
- **Project number:** 5R01AG082140-02
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** Mohanish P Deshmukh
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $622,753
- **Award type:** 5
- **Project period:** 2023-04-01 → 2027-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10817747

## Citation

> US National Institutes of Health, RePORTER application 10817747, miR-29: A brain homeostasis molecule for Alzheimer’s disease prevention (5R01AG082140-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10817747. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*